The board declared a special cash dividend of $2.00 per share, payable December 14, 2026 to holders of record as of November 30, 2026. Payment is conditioned on delivery of a customary CFO certificate, and the board may revoke or modify the dividend before payment.
NUTX · Nutex Health Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 69%
- Last earnings
- Nov 6, 2026
- Latest filing
- 10-Q · Nov 5
- Price history
- Apr 2022 to Nov 2026
Up next
Latest documents
Nutex Health reported nine-month 2026 revenue of $644.9 million, down 10.9%, while net income attributable to Nutex Health rose 159% to $152.9 million and operating cash flow reached $188.1 million.
Nutex Health’s arbitration costs totaled $27.8 million for the three months ended September 30, 2026 and $61.4 million for the nine months ended September 30, 2026, compared with $41.9 million and $116.2 million, respectively, in 2025.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | 211.43M | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Adjusted EBITDA attributable to Nutex Health non-GAAP | $211.4M | nine months ended September 30, 2026 | — |
|
|
|||
| EBITDA non-GAAP | 225.8M | Nine Months Ended September 30, 2026 | — |
|
|
|||
| EBITDA attributable to Nutex Health non-GAAP | $225.8M | nine months ended September 30, 2026 | — |
| Total cost of arbitration | $61.4M | nine months ended September 30, 2026 | — |
| Total visits at the Hospital Division | 154,326 | nine months ended September 30, 2026 | — |
|
|
|||
| Hospital facilities | 27 | as of the filing date | — |
| Patient visits | 49,962 | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NUTX
this stock
Nutex Health Inc.
|
$1.12B | -1.2% | +82.4% | — | 17.0% |
|
HCA
HCA Healthcare, Inc.
|
$99.34B | +1.9% | +7.1% | 15.8 | 2.3% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$31.59B | -2.2% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$20.95B | +32.4% | +0.9% | 7.6 | 2.2% |
|
EHC
Encompass Health Corp
|
$13.11B | +25.9% | +10.5% | 20.9 | 3.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 17, 2026
- This year
- 17
The board declared a special cash dividend of $2.00 per share, payable December 14, 2026 to holders of record as of November 30, 2026. Payment is conditioned on delivery of a customary CFO certificate, and the board may revoke or modify the dividend before payment.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NUTX | -6.4% | -22.4% | +30.1% | -18.7% | -1.2% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | +2.2% | -13.2% | +39.3% | -10.0% | -2.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.